PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Real-time Estimate Cboe BZX  -  10:19 2022-08-18 am EDT
9.905 USD   -2.32%
08/04PROTAGONIST THERAPEUTICS : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04PROTAGONIST THERAPEUTICS : Q2 Earnings Snapshot
AQ
08/04PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to Russell Microcap Value Index

06/24/2022 | 12:00am EDT

Protagonist Therapeutics, Inc.(NasdaqGM:PTGX) added to Russell Microcap Value Index


© S&P Capital IQ 2022
All news about PROTAGONIST THERAPEUTICS, INC.
08/04PROTAGONIST THERAPEUTICS : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
08/04PROTAGONIST THERAPEUTICS : Q2 Earnings Snapshot
AQ
08/04PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
08/04Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six ..
CI
08/04PROTAGONIST THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Provides Corp..
PU
07/19Protagonist Therapeutics Reports Granting of Inducement Award
PR
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 3000 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell Microcap Value Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) dropped from Russell 2000 Growth Index
CI
06/24PROTAGONIST THERAPEUTICS, INC.(NASDA : PTGX) added to Russell 2000 Value Index
CI
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 34,3 M - -
Net income 2022 -142 M - -
Net cash 2022 206 M - -
P/E ratio 2022 -3,56x
Yield 2022 -
Capitalization 498 M 498 M -
EV / Sales 2022 8,49x
EV / Sales 2023 37,6x
Nbr of Employees 127
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 10,14 $
Average target price 40,00 $
Spread / Average Target 294%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Research & Development Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-70.35%498
MODERNA, INC.-37.79%61 810
IQVIA HOLDINGS INC.-14.72%44 878
LONZA GROUP AG-26.39%43 629
SEAGEN INC.10.47%31 500
ALNYLAM PHARMACEUTICALS, INC.31.58%26 782